MSB 5.24% $1.11 mesoblast limited

Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L, page-249

  1. 162 Posts.
    lightbulb Created with Sketch. 15
    Yes I wholeheartedly echo your sentiments @col69 and as @The Yankee points out vested interests on all levels will seek financial reward rather than sound science The submission from Lassman Law reads just like any “experts report”. The problem arises when there’s no “Conflict of Interest” statement to accompany the submission Now that would be revealing too much. Every published scientific paper must now disclose who supports and funds their research. The same should be true for all FDA submissions
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.11
Change
0.055(5.24%)
Mkt cap ! $1.261B
Open High Low Value Volume
$1.05 $1.13 $1.04 $6.781M 6.207M

Buyers (Bids)

No. Vol. Price($)
3 43856 $1.11
 

Sellers (Offers)

Price($) Vol. No.
$1.11 66000 1
View Market Depth
Last trade - 16.10pm 05/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.